{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:40:17Z","timestamp":1768876817048,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with haematological malignancies (HMs) are highly vulnerable to COVID\u201019 due to their immunocompromised status, which leads to prolonged viral clearance and severe outcomes. Nirmatrelvir\/ritonavir has shown efficacy in reducing severity and mortality in high\u2010risk COVID\u201019 outpatients, but its effectiveness in hospitalized HM patients remains unclear. We conducted a retrospective study to assess the effectiveness of nirmatrelvir\/ritonavir on mortality and viral clearance in hospitalized HM patients with mild\u2010to\u2010moderate COVID\u201019 during China's first COVID\u201019 surge. Mortality rate and viral clearance time were the primary end\u2010points. Cox proportional hazards models were used to detect factors associated with mortality and viral clearance. A total of 116 HM patients, with a median age of 47.2\u2009years, hospitalized for a minimum of 5\u2009days with mild\u2010to\u2010moderate COVID\u201019, were included in this study. There was no difference in the 90\u2010day mortality rate between HM patients treated with nirmatrelvir\/ritonavir within 5\u2009days and those not treated (4.9% vs. 5.3%, <jats:italic>p<\/jats:italic>\u2009=\u20091.000). Nirmatrelvir\/ritonavir use within 5\u2009days reduced the time to viral clearance (hazard ratio [HR]\u2009=\u20091.59, 95% confidence interval [CI] 1.04\u20132.42). Nirmatrelvir\/ritonavir use within 5\u2009days in hospitalized HM patients with mild\u2010to\u2010moderate COVID\u201019 does not reduce mortality but accelerates viral clearance.<\/jats:p>","DOI":"10.1111\/bjh.20039","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T21:01:19Z","timestamp":1741726879000},"page":"1077-1085","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of nirmatrelvir\/ritonavir in hospitalized haematological malignancy patients with mild\u2010to\u2010moderate <scp>COVID<\/scp>\u201019: A retrospective study"],"prefix":"10.1111","volume":"206","author":[{"given":"Hongbin","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Hematology West China Hospital, Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology West China Hospital, Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-9965","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology West China Hospital, Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-9711","authenticated-orcid":false,"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology West China Hospital, Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"World Health Organization.WHO Chief Declares End to COVID\u201019 as a Global Health Emergency [Internet]. 2023 [cited 2024 Aug 31]. Available from:https:\/\/news.un.org\/en\/story\/2023\/05\/1136367"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6815"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.01.001"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012251"},{"key":"e_1_2_14_6_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid\u201019 vaccines in immunocompromised patients: systematic review and meta\u2010analysis","volume":"376","author":"Lee A","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26209"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0130"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(23)00815\u20100"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16030342"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28441"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443"},{"issue":"18","key":"e_1_2_14_15_1","first-page":"2239","article-title":"Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the omicron surge","volume":"141","author":"Tadmor T","year":"2023","journal-title":"Blood"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00729-2"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18895"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28443"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3057"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00430-3"},{"key":"e_1_2_14_21_1","unstructured":"Hematology ASO.Treatment of COVID\u201019 in Immunocompromised Patients With Hematologic Conditions [Internet]. 2022 [cited 2024 Aug 31]. Available from:https:\/\/www.hematology.org\/covid\u201019\/treatment\u2010of\u2010covid\u201019\u2010in\u2010immunocompromised\u2010patients\u2010with\u2010hematologic\u2010conditions"},{"key":"e_1_2_14_22_1","unstructured":"World Health Organization.Clinical Management of COVID\u201019 [Internet]. 2023 [cited 2024 Aug 31]. Available from:https:\/\/www.who.int\/teams\/health\u2010care\u2010readiness\/covid\u201019"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01938-5"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hcs2.36"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2910.230585"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101939"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100694"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003806"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.269134"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143361"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.5603\/AHP.a2022.0007"},{"key":"e_1_2_14_32_1","unstructured":"NCCN Guidelines.Prevention and Treatment of Cancer\u2010Related Infections (Version 2.2024) [Internet]. National Comprehensive Cancer Network. 2024 [cited 2024 Aug 31]. Available from:https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=3&id=1457"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280847"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00878-2"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00374-1"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad306"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad189"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09150-1"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02255-4"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.20039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T02:37:20Z","timestamp":1744339040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.20039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/bjh.20039"],"URL":"https:\/\/doi.org\/10.1111\/bjh.20039","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}